Cinryze 500 unit vial-diluents
Ended Awarded Last action
- Contract number
- SPE2DR26FCRU5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $64,098
Award facts
- Contract value 100% obligated
- $64,098.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $64,098.40 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for CINRYZE 500 Unit Vials with diluents. The award, issued on January 12, 2026, with an ultimate completion date of February 3, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that establishes multiple regional prime vendor contractors to supply pharmaceutical products and medical consumables to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal military pharmaceutical supply chain since its registration in the System for Award Management in 2001. The company's portfolio encompasses branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables, with recent delivery orders ranging from under $100 to exceeding $115,000. Under the PPV-G GEN V program's 30-month base period with three 30-month option periods extending through December 31, 2036, the contractor is positioned to deliver diverse and specialized pharmaceutical requirements to support recurring medical supply needs of military healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FCRU5?
SPE2DR26FCRU5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 12, 2026.
How much is contract SPE2DR26FCRU5 worth?
The government has obligated $64,098 on SPE2DR26FCRU5.
Is contract SPE2DR26FCRU5 an order under another contract?
Yes. SPE2DR26FCRU5 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRU5 competed?
The extent of competition for SPE2DR26FCRU5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award